Status:

ENROLLING_BY_INVITATION

Potential Biomarkers and Pathogenic Mechanism for Reflux Aspiration-induced Lung Injury.

Lead Sponsor:

Shanghai Zhongshan Hospital

Conditions:

ARDS, Human

Aspiration Pneumonia

Eligibility:

All Genders

18-99 years

Brief Summary

There is limited research on aspiration pneumonia-induced ARDS (Acute Respiratory Distress Syndrome), and currently there is a lack of studies on corresponding biomarkers and pathogenic mechanisms. We...

Detailed Description

Aspiration pneumonia leading to acute respiratory distress syndrome (ARDS) is not uncommon in clinical practice, but sometimes it occurs covertly and is not easily detected by doctors or family member...

Eligibility Criteria

Inclusion

  • The patient is between 18-99 years old. The patient meets the diagnostic criteria for ARDS upon admission to the ICU or during hospitalization, and requires mechanical ventilation with endotracheal intubation.
  • Within 24 hours of endotracheal intubation, bronchoscopy is performed for diagnostic or therapeutic purposes, and BALF is collected.
  • PH, amylase, and cytokines are tested within 24 hours. The patient, legal guardian, or authorized patient representative must voluntarily sign an informed consent form approved by the corresponding institutional review board. If the patient signs the consent form, the person obtaining consent must ensure that the patient is in a sufficient condition to provide informed consent.

Exclusion

  • Clinical diagnosis of left ventricular failure Lung cancer-primary or metastatic Hematologic malignancy Acute gastrointestinal bleeding precluding enteral feeding Severe immunosuppression, defined as cytotoxic therapy within 15 days or White blood cell count of 5000 7) Use of steroids: 0.25 mg/kg/day of prednisone (or an equivalent dose of corticosteroids) Use of nonsteroidal anti-inflammatory (including aspirin) drugs within the last 24 hrs Known to be HIV positive Moribond at entry Pregnancy or positive pregnancy test

Key Trial Info

Start Date :

November 28 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

November 28 2026

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT06164639

Start Date

November 28 2023

End Date

November 28 2026

Last Update

July 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zhongshan Hospital Fudan University

Shanghai, China